Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its upcoming second quarter 2024 financial results release and conference call. The company will report its Q2 2024 financial and operating results after market close on Tuesday, August 6, 2024. Following this, Voyager will host a conference call and webcast at 4:30 p.m. ET.
Interested participants can register for the telephone conference in advance through a provided link. A live webcast will be available on the Investors section of Voyager's website, with a replay accessible for at least 30 days after the call.
Voyager Therapeutics (Nasdaq: VYGR), una azienda biotecnologica specializzata in medicine neurogenetiche, ha annunciato la prossima pubblicazione dei risultati finanziari del secondo trimestre 2024 e una conferenza telefonica. L'azienda comunicherà i risultati finanziari e operativi del Q2 2024 dopo la chiusura del mercato martedì 6 agosto 2024. A seguire, Voyager ospiterà una conferenza telefonica e un webcast alle 16:30 ET.
I partecipanti interessati possono registrarsi in anticipo per la conferenza telefonica tramite un link fornito. Un webcast dal vivo sarà disponibile nella sezione Investitori del sito web di Voyager, con una registrazione accessibile per almeno 30 giorni dopo la chiamata.
Voyager Therapeutics (Nasdaq: VYGR), una empresa biotecnológica centrada en medicamentos neurogenéticos, ha anunciado la próxima publicación de los resultados financieros del segundo trimestre de 2024 y una conferencia telefónica. La empresa anunciará sus resultados financieros y operativos del Q2 2024 después del cierre del mercado el martes 6 de agosto de 2024. Después de esto, Voyager realizará una conferencia telefónica y un webcast a las 4:30 p.m. ET.
Los participantes interesados pueden registrarse con anticipación para la conferencia telefónica a través de un enlace proporcionado. Se ofrecerá un webcast en vivo en la sección de Inversores del sitio web de Voyager, con una repetición accesible durante al menos 30 días después de la llamada.
Voyager Therapeutics (Nasdaq: VYGR), 신경 유전자 의약품에 집중하는 생명공학 회사,가 다가오는 2024년 2분기 재무 결과 발표와 컨퍼런스 콜 일정을 발표했습니다. 회사는 2024년 8월 6일 화요일 시장 종료 후 Q2 2024의 재무 및 운영 결과를 보고할 것입니다. 그 이후에 Voyager는 오후 4시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다.
관심 있는 참가자는 제공된 링크를 통해 미리 전화 회의에 등록할 수 있습니다. 생방송 웹캐스트는 Voyager 웹사이트의 투자자 섹션에서 제공되며, 통화 이후 최소 30일 동안 다시 시청할 수 있습니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise biotechnologique spécialisée dans les médicaments neurogénétiques, a annoncé la prochaine publication de ses résultats financiers pour le deuxième trimestre 2024 et une conférence téléphonique. L'entreprise communiquera ses résultats financiers et opérationnels du T2 2024 après la fermeture du marché, le mardi 6 août 2024. Par la suite, Voyager organisera une conférence téléphonique et un webinaire à 16h30 ET.
Les participants intéressés peuvent s'inscrire à l'avance pour la conférence téléphonique via un lien fourni. Un webinaire en direct sera disponible dans la section Investisseurs du site Web de Voyager, avec un replay accessible pendant au moins 30 jours après l'appel.
Voyager Therapeutics (Nasdaq: VYGR), ein Biotech-Unternehmen, das sich auf neurogenetische Medikamente konzentriert, hat die bevorstehende Veröffentlichung der Finanzergebnisse für das zweite Quartal 2024 und eine Konferenzschaltung angekündigt. Das Unternehmen wird seine finanziellen und operativen Ergebnisse für das zweite Quartal 2024 nach Marktschluss am Dienstag, den 6. August 2024 bekannt geben. Im Anschluss daran wird Voyager eine Konferenzschaltung und ein Webcast um 16:30 Uhr ET veranstalten.
Interessierte Teilnehmer können sich im Voraus über einen bereitgestellten Link für die Telefonkonferenz anmelden. Ein Live-Webcast wird im Bereich Investoren der Website von Voyager verfügbar sein, mit einer Wiederholung, die mindestens 30 Tage nach dem Anruf zugänglich ist.
- None.
- None.
LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.
To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI796eccb31a2e48c9a71f6c41edd5c510. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
When will Voyager Therapeutics (VYGR) release its Q2 2024 financial results?
What time is Voyager Therapeutics' (VYGR) Q2 2024 earnings call scheduled for?
How can investors access Voyager Therapeutics' (VYGR) Q2 2024 earnings call?
Will a replay of Voyager Therapeutics' (VYGR) Q2 2024 earnings call be available?
